undamentalytics Newsletter
Sign in

Prelude Therapeutics Inc balance sheet

At the end of fiscal 2025, Prelude Therapeutics Inc had total assets of $141m, total liabilities of $72.7m and shareholders' equity of $68.6m. It held $35.3m in cash against $0 of debt: net cash of $35.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents123526
Total current assets136106155
Total assets176141189
Accounts payable842
Deferred revenue (current)03425
Total current liabilities265338
Total debt000
Total liabilities447356
Shareholders' equity13169134
Net debt (negative = net cash)−12−35−26

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: JANX vs PRLDCRSP vs PRLDABEO vs PRLD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prelude Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prelude Therapeutics Inc.